Navigation Links
Selective Marker Found to Indicate Aggressive Form of Breast Cancer

Researchers have linked a structural protein called nestin to a particularly deadly form of breast cancer, identifying a new biomarker that could lead to earlier detection and better treatment.//

In the January 15 issue of Cancer Research, researchers from Dartmouth Medical School demonstrate that nestin could represent a selective biological marker for basal epithelial breast tumors, a highly aggressive cancer with similarities to mammary stem cells, the regenerative cells believed to be the site of breast cancer initiation.

'Patients with this type of breast cancer are at high risk for recurrence,' said James DiRenzo, Ph.D., assistant professor at Dartmouth Medical School. 'Ideally, a marker like nestin would enable clinicians to monitor these patients through frequent tests of a biomarker and, in doing so, detect the cancer before it has a chance to come back.'

Basal epithelial tumors lack important molecular targets such as the estrogen receptor, progesterone receptor and Her2. This not only makes positive diagnosis difficult, say researchers, but also eliminates several important lines of therapy, such as tamoxifen or Herceptin, that work well for other breast cancer subtypes.

'Currently, there is no direct means of determining if a breast cancer is a basal epithelial tumor – doctors only know for certain once the other forms of breast cancer are ruled out,' DiRenzo said. 'This type of breast cancer is generally difficult to manage, but several important studies have shown that it is more likely than other breast cancer subtypes to respond to certain types of therapy, which highlights the need for a definitive diagnostic marker.'

The basal epithelial breast cancer subtype represents 17 to 37 percent of all breast cancers and is more common in premenopausal African American women than in other demographic groups. Among breast cancers, this subtype is known to have an early age of onset and a very short time between treatment and relapse. It is more commonly detected during normal screening mammogram intervals than other screening subtypes, which likely reflects its aggressive nature. These important clinical correlations likely explain why this subtype disproportionately accounts for breast cancer mortality, according to DiRenzo.

In a retrospective study of breast cancer tumors lacking estrogen receptors, progesterone receptors and Her2, DiRenzo and his colleagues found extremely high amounts of nestin in 14 of 16 tumor samples examined. While the researchers plan to strengthen their findings with a larger prospective study, their results offer a crucial first step in diagnosis and management of a disease that is notoriously difficult to control. Consistent with other studies showing that breast cancers associated with inherited mutations in BRCA1 display the basal phenotype, DiRenzo and colleagues found high levels of nestin in these tumors as well.

Nestin is a long filamentous protein found in adult stem cells in the central nervous system. While scientists do not know its exact function, the protein is thought to have a role in stabilizing the structure of adult stem cells as they regenerate and divide into daughter cells.

'Normal basal epithelial tissue produces nestin, but basal epithelial tumors produce a tremendous amount of nestin, which likely represents an abnormal expansion of the basal epithelia.' DiRenzo said. 'If it is indeed specific to regenerative cells, then it will make for an excellent diagnostic tool for a cancer of regenerative mammary cells.'

According to the DiRenzo, another important next step will be finding an efficient means of detecting nestin in a clinical screening setting. While it seems unlikely that a blood test would be sufficient, DiRenzo believes that a non-invasive test that collects samples from mammary ducts may enable the development of a screening tool for at-risk patient s.

Source-Newswise
'"/>




Related medicine news :

1. Selective eating just an evolutionary trait?
2. New Study Questions Cannibalism As A Worldwide Selective Force
3. Govt to Pass Amendment to Curb Sex Selective Abortions: Ramadoss
4. Selective Marker Found to Indicate Aggressive Form of Breast Cancer
5. Wiping Out Memories Selectively, is Possible Now
6. Blood Marker Found To Predict Colon Cancer
7. Biochemical Markers Might Help Predict Heart Problems
8. Elevated Insulin Levels To Influence Levels Of Inflammatory Markers
9. Protein Markers for Identification of Brain Tumor
10. Protein Expression to Serve as Marker for Head and Neck Cancer
11. A New Marker For Type-2 Diabetes ?
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2017)... ... , ... PracticeMatch, a company that provides online resources , job ... practitioners like nurse practitioners and physician assistants , will conduct its ... year. The online career fairs will allow job seekers to connect with healthcare employers ...
(Date:8/21/2017)... ... August 21, 2017 , ... Los Angeles area ... fellows for academic year 2017-2018, Christina M. Busuito, M.D. and Lukasz Swistun, M.D. ... in Plastic and Reconstructive Surgery. The candidate will have the opportunity to ...
(Date:8/21/2017)... ... August 21, 2017 , ... Five chefs from local senior ... Alzheimer’s Family Center. , Guests will be able to vote for their favorite ... Lamb Shank with Fennel Dill Salad, Feta Cheese Sauce & Garlic Pita Crisp, Greek ...
(Date:8/21/2017)... , ... August 21, 2017 , ... The experts have ... are we supposed to get things done in a healthy way these days? FlexiSpot, ... launching a crowdfunding campaign on August 28 to introduce Deskcise Pro™– the world’s first ...
(Date:8/21/2017)... ... August 21, 2017 , ... San Diego physician and surgeon ... reform plan, has announced his candidacy for the 52nd Congressional District currently held by ... America’s Promise. Coming to this country at age eleven after suffering homelessness and hardship ...
Breaking Medicine News(10 mins):
(Date:8/1/2017)... , Aug. 1, 2017   CerSci Therapeutics ... Dallas, Texas , has received notice from ... National Institutes of Health (NIH) that it has been ... grant totaling over $650,000 in 2017 with an additional ... CerSci,s Investigational New Drug application of their lead non-opioid ...
(Date:7/28/2017)... CHICAGO, July 28, 2017 Hill-Rom Holdings, Inc. ... fiscal third quarter ended June 30, 2017, and updated ... For the fiscal third quarter, ... to $0.68 per diluted share in the prior-year period. ... of $0.39 per diluted share primarily related to the ...
(Date:7/26/2017)... -- E.I. Medical Imaging (EIMI) has partnered with Dr. ... the worlds first ultrasound system to be used underwater to ... In preparation for a piece produced by Icon films ... Guttridge approached EIMI with the idea of an underwater ultrasound ... underwater. EIMI produces ...
Breaking Medicine Technology: